STYXL1

Summary

STYXL1 (serine/threonine/tyrosine interacting like 1, HGNC:18165) is a protein-coding gene on chromosome 7q11.23, encoding Serine/threonine/tyrosine-interacting-like protein 1 (Q9Y6J8). Catalytically inactive phosphatase.

Enables protein phosphatase binding activity and pseudophosphatase activity. Involved in negative regulation of stress granule assembly; positive regulation of intrinsic apoptotic signaling pathway; and positive regulation of neuron projection development. Located in mitochondrion.

Source: NCBI Gene 51657 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 79 total — 1 likely-pathogenic
• MANE Select transcript: NM_001317785

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18165
Approved symbol	STYXL1
Name	serine/threonine/tyrosine interacting like 1
Location	7q11.23
Locus type	gene with protein product
Status	Approved
Aliases	MK-STYX
Ensembl gene	ENSG00000127952
Ensembl biotype	protein_coding
OMIM	616695
Entrez	51657

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 31 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000248600, ENST00000340062, ENST00000359697, ENST00000360591, ENST00000430497, ENST00000431581, ENST00000438695, ENST00000451157, ENST00000454618, ENST00000460184, ENST00000474328, ENST00000884112, ENST00000884113, ENST00000884114, ENST00000884115, ENST00000884116, ENST00000884117, ENST00000884118, ENST00000884119, ENST00000884120, ENST00000884121, ENST00000884122, ENST00000884123, ENST00000884124, ENST00000884125, ENST00000884126, ENST00000929929, ENST00000929930, ENST00000929931, ENST00000929932, ENST00000929933, ENST00000929934, ENST00000971319, ENST00000971320, ENST00000971321

RefSeq mRNA: 6 — MANE Select: NM_001317785 NM_001317785, NM_001317786, NM_001317787, NM_001317788, NM_001317789, NM_016086

CCDS: CCDS5580, CCDS83193

Canonical transcript exons

ENST00000359697 — 9 exons

Exon	Start	End
ENSE00001146601	76013742	76013887
ENSE00001519919	75996342	75996599
ENSE00001519920	76030421	76030527
ENSE00001519923	76047662	76048000
ENSE00003537949	76005259	76005404
ENSE00003571834	76021851	76021992
ENSE00003574794	76028642	76028703
ENSE00003606846	76003758	76003855
ENSE00003641884	76000890	76001002

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 96.09.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.0368 / max 67.7322, expressed in 1812 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
84395	14.8737	1811
84394	1.1630	751

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	96.09	gold quality
lower esophagus mucosa	UBERON:0035834	95.17	gold quality
mucosa of transverse colon	UBERON:0004991	94.96	gold quality
islet of Langerhans	UBERON:0000006	94.52	gold quality
granulocyte	CL:0000094	94.29	gold quality
monocyte	CL:0000576	94.00	gold quality
leukocyte	CL:0000738	93.40	gold quality
mononuclear cell	CL:0000842	93.37	gold quality
body of pancreas	UBERON:0001150	93.21	gold quality
rectum	UBERON:0001052	92.83	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.80	gold quality
pancreas	UBERON:0001264	92.63	gold quality
nasal cavity epithelium	UBERON:0005384	92.44	gold quality
epithelium of bronchus	UBERON:0002031	92.00	gold quality
right testis	UBERON:0004534	92.00	gold quality
left testis	UBERON:0004533	91.95	gold quality
bronchus	UBERON:0002185	91.89	gold quality
right adrenal gland	UBERON:0001233	91.77	gold quality
bronchial epithelial cell	CL:0002328	91.72	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.58	gold quality
esophagus mucosa	UBERON:0002469	91.43	gold quality
nucleus accumbens	UBERON:0001882	91.37	gold quality
testis	UBERON:0000473	90.92	gold quality
right adrenal gland cortex	UBERON:0035827	90.90	gold quality
spinal cord	UBERON:0002240	90.88	gold quality
male germ cell	CL:0000015	90.69	gold quality
sperm	CL:0000019	90.69	gold quality
smooth muscle tissue	UBERON:0001135	90.69	gold quality
putamen	UBERON:0001874	90.53	gold quality
ventricular zone	UBERON:0003053	90.49	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EWSR1, FLI1

miRNA regulators (miRDB)

5 targeting STYXL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-2467-5P	97.36	67.71	991
HSA-MIR-3672	94.46	65.67	646
HSA-MIR-6864-3P	94.46	65.97	625

Literature-anchored findings (GeneRIF, showing 11)

• Results illustrated a role for MK-STYX in regulating the ability of G3BP1 to integrate changes in growth-factor stimulation and environmental stress with the regulation of protein synthesis. (PMID:20180778)
• MK-STYX regulates mitochondrial outer membrane permeabilization using a distinct mechanism. (PMID:21262771)
• The pseudophosphatase MK-STYX plays a key role in the cellular response to stress. (PMID:23163895)
• our data support a model in which MK-STYX controls apoptosis by negatively regulating PTPMT1. (PMID:24709986)
• this study revealed STYXL1 as a novel candidate gene for moderate intellectual disability, seizures and behavioral complexities. (PMID:25724587)
• We have detected this variant via whole exome sequencing in a homozygous state in two families. Segregation analyses in our families and thorough validation in international genetic databases provides evidence that this variant is most likely benign. This is important information for genetic counselling. The role of STYXL1 variants in human disease needs to be established (PMID:30472486)
• These findings show that MK-STYX decreases the number of HDAC6-containing aggregates and alters their localization, sustains microtubule acetylation, and increases detyrosination of microtubules, implicating MK-STYX as a signaling molecule in HDAC6 activity. (PMID:30909412)
• Silencing serine/threonine/tyrosine-interacting-like protein 1 (STYXL1) inhibited glioma cell growth, soft agar colony formation, migration, invasion, proliferation, and xenograft tumor growth [Review]. (PMID:31146910)
• STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway. (PMID:32271415)
• Pseudophosphatase STYXL1 depletion enhances glucocerebrosidase trafficking to lysosomes via ER stress. (PMID:37198709)
• The DUSP domain of pseudophosphatase MK-STYX interacts with G3BP1 to decrease stress granules. (PMID:37516290)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Styxl1	ENSMUSG00000019178
rattus_norvegicus	Styxl1	ENSRNOG00000023366

Paralogs (31): DUSP13B (ENSG00000079393), DUSP12 (ENSG00000081721), SSH1 (ENSG00000084112), DUSP3 (ENSG00000108861), PTPMT1 (ENSG00000110536), DUSP16 (ENSG00000111266), EPM2A (ENSG00000112425), DUSP22 (ENSG00000112679), DUSP1 (ENSG00000120129), DUSP4 (ENSG00000120875), DUSP9 (ENSG00000130829), DUSP26 (ENSG00000133878), DUSP5 (ENSG00000138166), DUSP6 (ENSG00000139318), SSH2 (ENSG00000141298), DUSP10 (ENSG00000143507), DUSP15 (ENSG00000149599), DUSP2 (ENSG00000158050), KASH5 (ENSG00000161609), DUSP19 (ENSG00000162999), DUSP7 (ENSG00000164086), DUSP18 (ENSG00000167065), SSH3 (ENSG00000172830), DUSP8 (ENSG00000184545), DUSP28 (ENSG00000188542), DUSP29 (ENSG00000188716), DUSP21 (ENSG00000189037), STYX (ENSG00000198252), STYXL2 (ENSG00000198842), DUSP14 (ENSG00000276023), DUSP13A (ENSG00000293543)

Protein

Protein identifiers

Serine/threonine/tyrosine-interacting-like protein 1 — Q9Y6J8 (reviewed: Q9Y6J8)

Alternative names: Dual specificity phosphatase inhibitor MK-STYX, Dual specificity protein phosphatase 24, Inactive dual specificity protein phosphatase MK-STYX, Map kinase phosphatase-like protein MK-STYX

All UniProt accessions (5): Q9Y6J8, A0A0C4DG63, C9J4H0, H0Y6C4, H7C1Y2

UniProt curated annotations — full annotation on UniProt →

Function. Catalytically inactive phosphatase. By binding to G3BP1, inhibits the formation of G3BP1-induced stress granules. Does not act by protecting the dephosphorylation of G3BP1 at ‘Ser-149’. Inhibits PTPMT1 phosphatase activity. By inhibiting PTPMT1, positively regulates intrinsic apoptosis. May play a role in the formation of neurites during neuronal development.

Subunit / interactions. Interacts with G3BP1. Interacts with PTPMT1; the interaction inhibits PTPMT1 catalytic activity.

Subcellular location. Mitochondrion matrix.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9Y6J8-1	1	yes
Q9Y6J8-2	2
Q9Y6J8-3	3
Q9Y6J8-4	4
Q9Y6J8-5	5

RefSeq proteins (6): NP_001304714, NP_001304715, NP_001304716, NP_001304717, NP_001304718, NP_057170 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000340	Dual-sp_phosphatase_cat-dom	Domain
IPR001763	Rhodanese-like_dom	Domain
IPR020422	TYR_PHOSPHATASE_DUAL_dom	Domain
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR036873	Rhodanese-like_dom_sf	Homologous_superfamily
IPR053272	STY_interacting-like	Family

Pfam: PF00581, PF00782

UniProt features (10 total): splice variant 6, domain 2, chain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6J8-F1	90.71	0.79

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
245–246	confers phosphatase activity. dephosphorylates g3bp1 at ‘ser-149’. loss of interaction with g3bp1. reduces arsenite-indu

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 121 (showing top): GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_NEGATIVE_REGULATION_OF_ORGANELLE_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, KESHELAVA_MULTIPLE_DRUG_RESISTANCE, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_ORGANELLE_ASSEMBLY, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN, DOUGLAS_BMI1_TARGETS_DN, GOBP_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT, chr7q11, GOBP_CELL_PROJECTION_ORGANIZATION

GO Biological Process (7): positive regulation of neuron projection development (GO:0010976), intracellular signal transduction (GO:0035556), negative regulation of stress granule assembly (GO:0062030), regulation of intrinsic apoptotic signaling pathway (GO:2001242), positive regulation of intrinsic apoptotic signaling pathway (GO:2001244), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (4): pseudophosphatase activity (GO:0001691), phosphatase inhibitor activity (GO:0019212), protein phosphatase binding (GO:0019903), protein binding (GO:0005515)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intrinsic apoptotic signaling pathway	2
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
intracellular anatomical structure	1
signal transduction	1
stress granule assembly	1
regulation of stress granule assembly	1
negative regulation of organelle assembly	1
regulation of intracellular signal transduction	1
regulation of apoptotic signaling pathway	1
positive regulation of intracellular signal transduction	1
positive regulation of apoptotic signaling pathway	1
regulation of intrinsic apoptotic signaling pathway	1
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
phosphatase inhibitor activity	1
enzyme inhibitor activity	1
phosphatase activity	1
phosphatase regulator activity	1
phosphatase binding	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STYXL1	G3BP1	Q13283	646
STYXL1	NUDT11	Q96G61	646
STYXL1	UHMK1	Q8TAS1	553
STYXL1	PRKCH	P24723	520
STYXL1	NXF3	Q9H4D5	477
STYXL1	TRIM39	Q9HCM9	450
STYXL1	LANCL1	O43813	442
STYXL1	FLAD1	Q8NFF5	433
STYXL1	ATXN1	P54253	403
STYXL1	TTLL9	Q3SXZ7	394
STYXL1	VMO1	Q7Z5L0	390
STYXL1	PTS	Q03393	389
STYXL1	TMEM120A	Q9BXJ8	367
STYXL1	NFATC2IP	Q8NCF5	365
STYXL1	POMC	P01189	364

IntAct

12 interactions, top by confidence:

A	B	Type	Score
STYXL1	ARMC8	psi-mi:“MI:0915”(physical association)	0.400
STYXL1	NEB	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	Tcr-alpha	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	DDOST	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	PSPH	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	RPS29	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	SRPRB	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	SMC1A	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	TLE5	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	ATXN10	psi-mi:“MI:0915”(physical association)	0.000
STYXL1	EHD4	psi-mi:“MI:0915”(physical association)	0.000
TRIM54	STYXL1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (44): ACTA1 (Affinity Capture-MS), MYO1B (Affinity Capture-MS), MYO1C (Affinity Capture-MS), SPTAN1 (Affinity Capture-MS), SPTBN1 (Affinity Capture-MS), VIM (Affinity Capture-MS), STYXL1 (Affinity Capture-RNA), AES (Affinity Capture-MS), SMC1A (Affinity Capture-MS), RPS29 (Affinity Capture-MS), ATXN10 (Affinity Capture-MS), EHD4 (Affinity Capture-MS), PSPH (Affinity Capture-MS), ATXN1 (Affinity Capture-Western), STYXL1 (Affinity Capture-RNA)

ESM2 similar proteins: A2VE14, A5D9H7, B2GV54, B9EKX1, D0RB01, F1M625, F1NBL0, O35684, O54760, O54761, O60242, O60656, O75317, P13591, P31836, P35237, P35290, P62068, P62069, P69849, Q3UQ28, Q3ZCW2, Q4R3G2, Q5JPE7, Q5NVN7, Q5R5K6, Q5R899, Q5RBQ4, Q5RKN4, Q5T4D3, Q5VU57, Q5ZHQ2, Q5ZIN0, Q6ZW05, Q80ZF8, Q8BLF1, Q8BUV3, Q90935, Q90W79, Q969Q5

Diamond homologs: A4IHU7, B4F7B7, O09112, O13453, O54838, O55737, O95147, P0C591, P0C593, P0C594, P0C595, P0C596, P0C598, P0C599, P0C5A0, P28562, P28563, P38148, P38590, P40479, P43078, Q02256, Q0IID7, Q13202, Q16828, Q16829, Q17QJ3, Q17QM8, Q1LWL2, Q2KJ36, Q39491, Q4G0W2, Q4RQD3, Q4V7N3, Q54R42, Q54T76, Q55CS7, Q55E39, Q566R7, Q5APU2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	54
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
563386	GRCh37/hg19 7q11.23(chr7:75082354-76007380)x1	Likely pathogenic

SpliceAI

1713 predictions. Top by Δscore:

Variant	Effect	Δscore
7:76003753:CTTA:C	donor_loss	1.0000
7:76003756:A:AC	donor_gain	1.0000
7:76003756:A:AT	donor_loss	1.0000
7:76003757:C:CC	donor_gain	1.0000
7:76003851:CAAAA:C	acceptor_gain	1.0000
7:76003853:AAA:A	acceptor_gain	1.0000
7:76003854:AA:A	acceptor_gain	1.0000
7:76003856:C:CC	acceptor_gain	1.0000
7:76005253:A:AC	donor_gain	1.0000
7:76005254:C:CC	donor_gain	1.0000
7:76005254:CT:C	donor_loss	1.0000
7:76005255:TT:T	donor_loss	1.0000
7:76005257:A:AC	donor_gain	1.0000
7:76005257:A:C	donor_loss	1.0000
7:76005258:C:CC	donor_gain	1.0000
7:76005258:CA:C	donor_gain	1.0000
7:76005258:CAA:C	donor_gain	1.0000
7:76005258:CAAG:C	donor_gain	1.0000
7:76005258:CAAGG:C	donor_gain	1.0000
7:76005410:G:C	acceptor_gain	1.0000
7:76005410:G:GC	acceptor_gain	1.0000
7:76005412:G:C	acceptor_gain	1.0000
7:76021988:TTTTT:T	acceptor_gain	1.0000
7:76021994:T:C	acceptor_gain	1.0000
7:76021994:T:TC	acceptor_gain	1.0000
7:76028700:ACATC:A	acceptor_loss	1.0000
7:76028701:CAT:C	acceptor_gain	1.0000
7:76028702:ATCT:A	acceptor_loss	1.0000
7:76028703:TCTGG:T	acceptor_loss	1.0000
7:76028704:C:CC	acceptor_gain	1.0000

AlphaMissense

2088 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:75996524:A:G	W296R	0.988
7:75996524:A:T	W296R	0.988
7:76013793:G:C	F134L	0.988
7:76013793:G:T	F134L	0.988
7:76013794:A:G	F134S	0.988
7:76013795:A:G	F134L	0.988
7:76005286:A:T	V191D	0.987
7:76028658:G:T	A50D	0.986
7:76030421:C:G	D35H	0.986
7:75996520:T:A	E297V	0.985
7:76000941:A:C	S253R	0.985
7:76000941:A:T	S253R	0.985
7:76000943:T:G	S253R	0.985
7:76000972:A:G	L243P	0.983
7:76028698:G:T	R37S	0.983
7:75996532:A:G	L293P	0.981
7:76000965:A:C	F245L	0.980
7:76000965:A:T	F245L	0.980
7:76000967:A:G	F245L	0.980
7:76013775:A:C	F140L	0.980
7:76013775:A:T	F140L	0.980
7:76013777:A:G	F140L	0.980
7:76030473:A:C	N17K	0.980
7:76030473:A:T	N17K	0.980
7:76005293:C:G	A189P	0.979
7:76005332:C:G	A176P	0.979
7:76005379:G:T	P160H	0.979
7:76013824:A:T	V124D	0.979
7:76021931:A:T	V76E	0.979
7:76000964:A:G	S246P	0.978

dbSNP variants (sampled 300 via entrez): RS1000119984 (7:76011403 A>G), RS1000499765 (7:76026852 G>A), RS1000516748 (7:76011237 T>G), RS1000639110 (7:76021232 C>A), RS1000759506 (7:76022432 G>A), RS1000836996 (7:76000150 G>A), RS1000942139 (7:76005913 G>A), RS1000946302 (7:76044974 C>A,T), RS1001030789 (7:76032657 G>A), RS1001058500 (7:76032956 C>T), RS1001100493 (7:76038557 C>A,G), RS1001236963 (7:76000006 G>C), RS1001363947 (7:76023691 C>T), RS1001567479 (7:76008477 C>G), RS1001661820 (7:76047611 T>C)

Disease associations

OMIM: gene MIM:616695 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004599_52	Mean platelet volume	1.000000e-14
GCST011124_4	Caffeine consumption from tea	7.000000e-22
GCST011126_17	Caffeine consumption from coffee or tea	4.000000e-56
GCST90002381_238	Eosinophil count	2.000000e-12

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0010091	tea consumption measurement
EFO:0006781	coffee consumption measurement
EFO:0004842	eosinophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	4
Tunicamycin	increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
daidzein	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
daidzin	affects cotreatment, decreases expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
genistin	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
glycitein	decreases expression, affects cotreatment	1
2-palmitoylglycerol	increases expression	1
glycitin	affects cotreatment, decreases expression	1
abrine	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Camptothecin	decreases response to substance	1
Methotrexate	decreases expression	1
Selenium	increases expression	1
Tretinoin	increases expression	1
Urethane	decreases expression	1
Vitamin E	increases expression	1
Cyclosporine	increases expression	1
Cadmium Chloride	increases abundance, increases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9TI	Ubigene HEK293 STYXL1 KO	Transformed cell line	Female
CVCL_E0QD	Ubigene HeLa STYXL1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.